Order Article Reprints

Abouzayed A, Tano H, Nagy Á, Rinne SS, Wadeea F, Kumar S, Westerlund K, Tolmachev V, Eriksson Karlström A, Orlova A. Preclinical Evaluation of the GRPR-Targeting Antagonist RM26 Conjugated to the Albumin-Binding Domain for GRPR-Targeting Therapy of Cancer. Pharmaceutics. 2020; 12(10):977. https://doi.org/10.3390/pharmaceutics12100977

Abouzayed, Ayman, Hanna Tano, Ábel Nagy, Sara S. Rinne, Fadya Wadeea, Sharmishtaa Kumar, Kristina Westerlund, Vladimir Tolmachev, Amelie Eriksson Karlström, and Anna Orlova. 2020. "Preclinical Evaluation of the GRPR-Targeting Antagonist RM26 Conjugated to the Albumin-Binding Domain for GRPR-Targeting Therapy of Cancer" Pharmaceutics 12, no. 10: 977. https://doi.org/10.3390/pharmaceutics12100977

Abouzayed, A., Tano, H., Nagy, Á., Rinne, S. S., Wadeea, F., Kumar, S., Westerlund, K., Tolmachev, V., Eriksson Karlström, A., & Orlova, A. (2020). Preclinical Evaluation of the GRPR-Targeting Antagonist RM26 Conjugated to the Albumin-Binding Domain for GRPR-Targeting Therapy of Cancer. Pharmaceutics, 12(10), 977. https://doi.org/10.3390/pharmaceutics12100977